Experience with rituximab in refractory idiopathic inflammatory myopathy

Authors

  • Elmer R. García-Salazar Unidad Ambulatoria de Reumatología (UNAR), Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú. Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú. Docente invitado, Facultad de Medicina Humana, Universidad Nacional Mayor de San Marcos, Lima, Perú.
  • Felipe Becerra Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú. Docente, Facultad de Medicina Humana, UNMSM, Lima, Perú.
  • José Chávez Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú. Docente, Facultad de Medicina Humana, UNMSM, Lima, Perú.

DOI:

https://doi.org/10.15381/anales.v74i4.2709

Keywords:

Dermatomyositis, refractory idiopathic inflammatory myopathy, rituximab.

Abstract

Clinical and laboratory characteristics of two patients who received rituximab for refractory idiopathic inflammatory myopathy (IIM) are described. Patients were refractory to conventional treatment with disease-modifying antirheumatic drugs (DMARDs) so they received rituximab 1 g dose every 14 days in two biannual cycle infusions. Data of proximal muscle strength, pathognomonic skin lesions, CPK, SGOT, LDH and ESR, results of electromyography, muscle and skin biopsy were obtained from the medical records. None of the cases presented drug reaction or infections during and following infusions. Rituximab showed effectiveness in clinical and enzymatic response in patients with dermatomyositis refractory to corticosteroids and traditional DMARDs.

Downloads

Published

2013-12-30

Issue

Vol. 74 No. 4 (2013)

Section

Casos clínicos

License

Copyright (c) 2013 Elmer R. García-Salazar, Felipe Becerra, José Chávez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
García-Salazar ER, Becerra F, Chávez J. Experience with rituximab in refractory idiopathic inflammatory myopathy. An Fac med [Internet]. 2013 Dec. 30 [cited 2024 Jun. 30];74(4):331-4. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2709